clinical trial · NCT06590857
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
RayzeBio, Inc.·phase2·active not recruiting·n = 16
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast CancerAdvanced Breast CancerRYZ101
brief summary
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
started
Jul 19, 2024
primary completion
Oct 1, 2028
completion
Jan 1, 2033
last updated
Mar 18, 2026
official title
Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates and/or Chemotherapy (TRACY-1).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol